RU97108980A - Derivatives of benzimidazole, antihistamine pharmaceutical composition and method for the treatment of allergic diseases - Google Patents

Derivatives of benzimidazole, antihistamine pharmaceutical composition and method for the treatment of allergic diseases

Info

Publication number
RU97108980A
RU97108980A RU97108980/04A RU97108980A RU97108980A RU 97108980 A RU97108980 A RU 97108980A RU 97108980/04 A RU97108980/04 A RU 97108980/04A RU 97108980 A RU97108980 A RU 97108980A RU 97108980 A RU97108980 A RU 97108980A
Authority
RU
Russia
Prior art keywords
ethyl
phenyl
compound according
benzimidazole
base
Prior art date
Application number
RU97108980/04A
Other languages
Russian (ru)
Other versions
RU2182150C2 (en
Inventor
Орхалес Аурелио
Рубио Виктор
Бордель Маравильяс
Original Assignee
Фабрика Эспаньола де Продуктос Кимикос и Фармасеутикос, С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from ES09601236A external-priority patent/ES2124167B1/en
Application filed by Фабрика Эспаньола де Продуктос Кимикос и Фармасеутикос, С.А. filed Critical Фабрика Эспаньола де Продуктос Кимикос и Фармасеутикос, С.А.
Publication of RU97108980A publication Critical patent/RU97108980A/en
Application granted granted Critical
Publication of RU2182150C2 publication Critical patent/RU2182150C2/en

Links

Claims (9)

1. Производные бензимидазола формулы
Figure 00000001

в которой R1 представляет водород или углеводородную группу с короткой цепью, такую, как метил, этил, изопропил, циклопропил или винил;
R2 представляет группу, выбранную из СН2ОН, СООН, СООR3 и 4,4-диметил-2-оксазолинила, причем R3 является алкильной группой с короткой цепью, как определено выше,
и их аддитивные соли с фармакологически приемлемыми кислотами или основаниями.1. Benzimidazole derivatives of the formula
Figure 00000001

in which R 1 represents hydrogen or a hydrocarbon group with a short chain, such as methyl, ethyl, isopropyl, cyclopropyl or vinyl;
R 2 represents a group selected from CH 2 OH, COOH, COOR 3 and 4,4-dimethyl-2-oxazolinyl, and R 3 is an alkyl group with a short chain, as defined above,
and their addition salts with pharmacologically acceptable acids or bases. 2. Соединение по п.1, которое является 1-(2-этоксиэтил)-2-[1-(2-(4-(1-(4,4-диметил-Δ2-оксазолин-2-ил)-1-метилэтил)-фенил)этил)пиперидин-4-ил] -1Н-бензимидазолом или его аддитивной солью с фармацевтически приемлемой кислотой или основанием.2. The compound according to claim 1, which is 1- (2-ethoxyethyl) -2- [1- (2- (4- (1- (4,4-dimethyl-Δ 2 -oxazolin-2-yl) -1 -methylethyl) phenyl) ethyl) piperidin-4-yl] -1H-benzimidazole or its additive salt with a pharmaceutically acceptable acid or base. 3. Соединение по п. 1, которое является 2-[4-(2-(4-(1-(2-этоксиэтил)бензимидазол-2-ил)пиперидин-1-ил)этил)фенил]-2-метилпропанойной кислотой или его аддитивной солью с фармацевтический приемлемой кислотой или основанием. 3. The compound according to claim 1, which is 2- [4- (2- (4- (1- (2-ethoxyethyl) benzimidazol-2-yl) piperidin-1-yl) ethyl) phenyl] -2-methylpropanoic acid or its additive salt with a pharmaceutical acceptable acid or base. 4. Соединение по п.1, которое является этил 2-[4-(2-(4-(1-(2-этоксиэтил)бензимидазол-2-ил)пиперидин-1-ил)этил)фенил] -2-метилпропаноатом или его аддитивной солью с фармацевтически приемлемой кислотой или основанием. 4. The compound according to claim 1, which is ethyl 2- [4- (2- (4- (1- (2-ethoxyethyl) benzimidazol-2-yl) piperidin-1-yl) ethyl) phenyl] -2-methylpropanoate or its additive salt with a pharmaceutically acceptable acid or base. 5. Соединение по п.1, которое является 1-(2-этоксиэтил)-2-[1-(2-(4-(1-(1,1-диметил-2-гидроксиэтил)фенил)этил)пиперидин-4-ил]-1Н-бензимидазолом или его аддитивной солью с фармацевтически приемлемой кислотой или основанием. 5. The compound according to claim 1, which is 1- (2-ethoxyethyl) -2- [1- (2- (4- (1- (1,1-dimethyl-2-hydroxyethyl) phenyl) ethyl) piperidine-4 -yl] -1H-benzimidazole or its additive salt with a pharmaceutically acceptable acid or base. 6. Соединение по п.1, которое является 1-(2-гидроксиэтил)-2-[1-(2-(4-(1-(4,4-диметил-Δ2-оксазолин-2-ил)-1-метилэтил)-фенил)этил)пиперидин-4-ил] -1Н-бензимидазолом или его аддитивной солью с фармацевтически приемлемой кислотой или основанием.6. The compound according to claim 1, which is 1- (2-hydroxyethyl) -2- [1- (2- (4- (1- (4,4-dimethyl-Δ 2 -oxazolin-2-yl) -1 -methylethyl) phenyl) ethyl) piperidin-4-yl] -1H-benzimidazole or its additive salt with a pharmaceutically acceptable acid or base. 7. Соединение по п. 1, которое является 2-[4-(2-(4-(1-(2-гидроксиэтил)бензимидазол-2-ил)пиперидин-1-ил)этил)фенил] -2-метилпропановой кислотой или ее аддитивной солью с фармацевтически приемлемой кислотой или основанием. 7. The compound according to claim 1, which is 2- [4- (2- (4- (1- (2-hydroxyethyl) benzimidazol-2-yl) piperidin-1-yl) ethyl) phenyl] -2-methylpropanoic acid or its additive salt with a pharmaceutically acceptable acid or base. 8. Антигистаминная фармацевтическая композиция, отличающаяся тем, что она содержит эффективное в качестве антигистаминного количество одного из соединений по пп.1-7 в качестве активного ингредиента, смешанное с одним или несколькими наполнителями. 8. Antihistamine pharmaceutical composition, characterized in that it contains an effective as an antihistamine amount of one of the compounds of claims 1 to 7 as an active ingredient, mixed with one or more excipients. 9. Способ лечения аллергических заболеваний у пациентов, который включает введение фармацевтической композиции по п.8 в подходящих дозах. 9. A method of treating allergic diseases in patients, which includes the introduction of the pharmaceutical composition of claim 8 in suitable doses.
RU97108980/04A 1996-06-04 1997-06-03 Derivatives of benzimidazole, antihistaminic pharmaceutical composition and method of treatment of allergic diseases RU2182150C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES09601236A ES2124167B1 (en) 1996-06-04 1996-06-04 NEW DERIVATIVES OF BENZMIDAZOLE WITH ANTIHISTAMINE ACTIVITY.
ESP9601236 1996-06-04

Publications (2)

Publication Number Publication Date
RU97108980A true RU97108980A (en) 1999-04-27
RU2182150C2 RU2182150C2 (en) 2002-05-10

Family

ID=8295035

Family Applications (1)

Application Number Title Priority Date Filing Date
RU97108980/04A RU2182150C2 (en) 1996-06-04 1997-06-03 Derivatives of benzimidazole, antihistaminic pharmaceutical composition and method of treatment of allergic diseases

Country Status (27)

Country Link
US (1) US5877187A (en)
EP (1) EP0818454B1 (en)
JP (1) JP4218991B2 (en)
CN (1) CN1105716C (en)
AR (1) AR008386A1 (en)
AT (1) ATE264317T1 (en)
AU (1) AU725700B2 (en)
BR (1) BR9703276A (en)
CA (1) CA2206754C (en)
CZ (1) CZ289278B6 (en)
DE (2) DE69728608T2 (en)
DK (1) DK0818454T3 (en)
ES (1) ES2124167B1 (en)
FR (1) FR11C0023I2 (en)
HR (1) HRP970307B1 (en)
HU (1) HU227598B1 (en)
IN (1) IN186319B (en)
LU (1) LU91798I2 (en)
MX (1) MXPA97004127A (en)
NO (2) NO313195B1 (en)
PL (1) PL188908B1 (en)
PT (1) PT818454E (en)
RU (1) RU2182150C2 (en)
SI (1) SI0818454T1 (en)
TR (1) TR199700464A2 (en)
TW (1) TW438794B (en)
ZA (1) ZA974893B (en)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL345247A1 (en) 1998-07-01 2001-12-03 Takeda Chemical Industries Ltd Retinoid-associated receptor regulators
US6448271B1 (en) 1998-11-27 2002-09-10 Basf Aktiengesellschaft Substituted benzimidazoles and their use as parp inhibitors
ES2151442B1 (en) * 1999-01-11 2001-07-01 Espanola Prod Quimicos NEW DERIVATIVE OF BENCENOETHANOL.
US6826561B2 (en) 2000-05-22 2004-11-30 Broadcom Corporation Method and apparatus for performing a binary search on an expanded tree
EP1505066B1 (en) * 2002-04-19 2006-12-06 Faes Farma, S.A. Polymorph of acid 4-[2-[4-[1-(2-ethoxyethyl)-1h-benzimidazole-2-il]-1-piperidinyl]ethyl]-alpha, alpha-dimethyl-benzeneacetic
US20070188330A1 (en) * 2006-01-24 2007-08-16 Morhard Robert C System and method for detecting, monitoring, tracking and identifying explosive materials using ID marks
US7247623B2 (en) * 2005-08-19 2007-07-24 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with non-drying antihistamines
KR101123903B1 (en) * 2008-02-12 2012-03-23 주식회사유한양행 Process for preparation of 2-methyl-2'-phenylpropionic acid derivatives and novel intermediate compounds
JP2010013472A (en) * 2009-09-09 2010-01-21 Faes Farma Sa POLYMORPH OF 4-[2-[1-(2-ETHOXYETHYL)-1H-BENZIMIDAZOL-2-YL]-1-PIPERIDINYL] ETHYL-alpha,alpha-DIMETHYL BENZENOACETIC ACID
CN102675101B (en) * 2012-05-16 2014-01-29 王蕾 Preparation method of 2-(4-haloethyl) phenyl-2-methyl propionic ester and synthesis method of bilastine
CZ307500B6 (en) 2012-08-15 2018-10-24 Zentiva, K.S. A method of the preparation of a 2-methyl-2'-phenylpropionic acid derivative employing novel intermediates
WO2014149019A1 (en) * 2013-03-15 2014-09-25 Hercules Incorporated Composition and method of producing personal care compositions with improved deposition properties
CN103214454A (en) * 2013-03-30 2013-07-24 北京万全德众医药生物技术有限公司 Bilastine crystal and preparation method thereof
CN103214455B (en) * 2013-03-30 2018-08-31 北京万全德众医药生物技术有限公司 A kind of preparation method of bilastine
WO2014188453A2 (en) * 2013-05-24 2014-11-27 Msn Laboratories Private Limited Novel process for the preparation of 2-[4-(2-{4-[1-(2-ethoxyethyl)-1h-benzimidazol-2-yl]-1-piperidinyl}ethyl) phenyl]-2-methylpropanoic acid
CN103351380B (en) * 2013-06-30 2019-01-22 北京万全德众医药生物技术有限公司 A method of preparing bilastine
CN104447683A (en) * 2013-09-12 2015-03-25 天津市汉康医药生物技术有限公司 Stable Bilastine compound
CN103896915A (en) * 2014-04-01 2014-07-02 中国药科大学 Benzimidazole derivative and preparation method thereof as well as application of benzimidazole derivative in medicine
EP3040334A1 (en) 2014-12-29 2016-07-06 Faes Farma, S.A. New benzimidazole derivatives as antihistamine agents
CN106349214B (en) * 2015-07-13 2020-11-03 南京长澳医药科技有限公司 Preparation method of bilastine impurity
ES2874577T3 (en) * 2015-07-24 2021-11-05 Urquima Sa Crystalline forms of bilastine and procedures for their preparation
CN105272977A (en) * 2015-09-19 2016-01-27 万全万特制药江苏有限公司 Bilastine intermediate preparation method
EP3170817A1 (en) 2015-11-20 2017-05-24 Faes Farma, S.A. Co-crystals of benzimidazole compounds
EP3170816A1 (en) 2015-11-20 2017-05-24 Faes Farma, S.A. Supersaturated compositions of benzimidazole compounds
WO2017167949A1 (en) 2016-04-01 2017-10-05 Krka, D.D., Novo Mesto Crystalline forms of bilastine
EP3452462A4 (en) * 2016-05-05 2019-10-23 MSN Laboratories Private Limited, R&D Center Solid state forms of 2-[4-(2-{4-[1-(2-ethoxyethyl)-1h-benzimidazol-2-yl]-1-piperidinyl}ethyl)phenyl]-2-methylpropanoic acid and process for preparation thereof
CN107365298A (en) * 2017-03-14 2017-11-21 罗欣生物科技（上海）有限公司 A kind of preparation method of the benzyl propionate derivant of 2 methyl 2 '
CN109456316A (en) * 2017-09-06 2019-03-12 万全万特制药江苏有限公司 A kind of preparation method of bilastine impurity
ES2813561T3 (en) 2017-09-07 2021-03-24 Tiefenbacher Alfred E Gmbh & Co Kg Pharmaceutical composition in tablet comprising bilastine
EP3681475B1 (en) 2017-10-16 2020-12-09 Faes Farma, S.A. Aqueous compositions comprising bilastine and mometasone
PL3641735T3 (en) 2017-12-18 2021-09-06 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Pharmaceutical tablet composition comprising bilastine form 3 and a water-soluble filler
EP3470062B1 (en) 2017-12-18 2020-10-28 Alfred E. Tiefenbacher (GmbH & Co. KG) Pharmaceutical tablet composition comprising bilastine polymorphic form 3 and magnesium aluminometasilicate
PT3740191T (en) 2018-01-18 2021-07-09 Faes Farma Sa Ophthalmic compositions comprising bilastine, a beta-cyclodextrin and at least one gelling agent
CN109081827A (en) * 2018-11-06 2018-12-25 北京天弘天达医药科技股份有限公司 A kind of preparation method and application of bilastine
EP3725298A1 (en) 2019-04-16 2020-10-21 Faes Farma, S.A. Stable and preserved pharmaceutical compositions of bilastine
EP4188339A1 (en) 2020-07-30 2023-06-07 Faes Farma, S.A. Decongestant drug delivery system
CN112110893A (en) * 2020-10-28 2020-12-22 山东齐环医药科技有限公司 Preparation method of bilastine
WO2022106923A1 (en) 2020-11-18 2022-05-27 BioPharma Synergies, S. L. Orodispersible powder composition comprising an antihistamine compound
EP4267109A1 (en) 2020-12-23 2023-11-01 Noucor Health S.A. A non-micronized bilastine composition
WO2023156559A1 (en) 2022-02-17 2023-08-24 Faes Farma, S.A. Bilastine composition for once-daily parenteral administration

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2048109B1 (en) * 1992-07-20 1994-12-16 Espanola Prod Quimicos PROCEDURE FOR THE PREPARATION OF NEW PIPERIDIC DERIVATIVES OF BENCIMIDAZOLE.
AU675240B2 (en) * 1992-08-03 1997-01-30 Sepracor, Inc. Terfenadine metabolites and their optically pure isomers for treating allergic disorders
ES2190442T3 (en) * 1993-06-25 2003-08-01 Merrell Pharma Inc NEW INTERMEDIATE PRODUCTS FOR THE PREPARATION OF DERIVATIVES OF 4-DIFENILMETIL / DIFENILMETOXI PIPERIDINA ANTIHISTAMINICOS.

Similar Documents

Publication Publication Date Title
RU97108980A (en) Derivatives of benzimidazole, antihistamine pharmaceutical composition and method for the treatment of allergic diseases
PE20050349A1 (en) ARIL OR HETEROARIL AMIDE COMPOUNDS
RU96120189A (en) NEW PHARMACEUTICAL DRUGS AND METHODS FOR PRODUCING THEM
CA2407149A1 (en) Melanin-concentrating hormone antagonist
CA2100503C (en) Piperidine derivatives of benzimidazole
RU2004126957A (en) PIPERIDINE DERIVATIVES
RU2001121186A (en) Derivatives of pyrazolecarboxylic acid, their preparation, pharmaceutical compositions containing them
RU2000116011A (en) ORAL PHARMACEUTICAL PHARMACEUTICAL FORM WITH LONG-TERM
KR960010000A (en) Catechol diether compounds as inhibitors of tumor necrosis factor (TNF) production
RU2002114809A (en) Quinazoline derivatives as vascular endothelial growth factor (VEGF) inhibitors
DE69733478D1 (en) ETHER-muscarinic antagonist
JP2003506406A5 (en)
JP2010531345A5 (en)
RU2000129161A (en) DERIVATIVE 1 - [(1-SUBSTITUTED-4-PIPERIDINYL) METHYL] -4-PIPERIDINE, METHOD FOR ITS PRODUCTION, PHARMACEUTICAL COMPOSITION CONTAINING THE INDICATED COMPOUND, AND THE INTERMEDIATE PRODUCT
AR016422A1 (en) PIPERIDINYLAMINOMETIL TRIFLUOROMETILO CYCLIC ESTERS COMPOUNDS AS AN ANTAGONIST OF THE SUBSTANCE P; PHARMACEUTICAL COMPOSITIONS AND PROCESSING PROCESSING.
RU2004119963A (en) HIV INTEGRAS INHIBITORS
DE69105135T2 (en) PIPERIDYL SUBSTITUTED INDOLE.
RU2003131970A (en) 4- (Phenyl-piperidine-4-ylidene-methyl) -benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders
RU2002110328A (en) Substituted benzimidazole preparation
RU2004111359A (en) COMBINED AGENTS FOR TREATMENT OF GLAUCOMA
KR870004955A (en) Various N-substituted 3-piperidinecarboxylic acids or N-substituted 3-pyridinecarboxylic acids and derivatives thereof
PE20040668A1 (en) NEW PIPERIDINE DERIVATIVES
DE60127535D1 (en) PREVENTIVE OR THERAPEUTIC AGENTS AGAINST GASTRIC OR OESOPHAGEAL REGURGITATION
AR023292A1 (en) A COMPOUND DERIVED FROM IMIDAZOL, A PROCEDURE FOR ITS PREPARATION, AND A MEDICINAL AND A PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND
RU2008105987A (en) NEW PIPERIDINE DERIVATIVES